1. Introduction {#s0005}
===============

Cytochrome P450 (CYP) is a superfamily of drug-metabolizing enzymes that is involved in the metabolism of endogenous compounds, xenobiotics and pharmaceuticals ([@b1000]). The major CYP involved in the hepatic metabolism of most of the drugs include CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 ([@b1000], [@b0015]). Since CYP is involved in phase-1 metabolism of \>70% of prescription drugs, modulation of its expressions is a major cause of adverse drug-drug interactions, including decreased drug efficacy ([@b0115], [@b0125]). Expression of CYP3A4 is markedly induced both *in vivo* and in cultured human hepatocytes *in vitro* in response to a variety of xenobiotics (eg., dexamethasone and rifampicin) as well as medicinal herbs like, St. John's wort (*Hypericum perforatum*) ([@b0065], [@b0105], [@b0135], [@b0035], [@b0100], [@b0080]).

Further, gene expression of CYP is regulated by a set of nuclear receptors in response to a wide spectrum of xenobiotics ([@b0095], [@b0100], [@b0015]). Of these, the pregnane X receptor (PXR), also known as xenobiotic or pregnane-activated receptor regulates CYP3A4 gene induction ([@b0075], [@b0040]). The most common clinical implication for the PXR activation is the drug-drug interactions, mediated by the upregulation of CYP3A4. Notably, PXR itself is activated by rifampicin and other xenobiotics ([@b0070]) as well as plant secondary metabolites like, hyperforin from *H. perforatum* ([@b0135], [@b0080]). In addition to this, PXR and its target genes also play an important role in maintaining normal physiological function and homeostasis. For example, artemisinin (*Artemisia annua*), piperine (*Piper nigrum*) and notoginsenoside (*Panax notoginseng*), the known activators of PXR, have been shown to prevent severity of colonic inflammatory bowel disease by inducing CYP3A4 expression ([@b0045], [@b0050], [@b0130]).

Hepatic PXR has broad substrate specificity and thus may be activated by a large number of chemically-diverse secondary metabolites found in dietary supplements and therapeutic herbs. Since such natural products are often orally consumed, the high concentration of their phytoconstituents in gut and liver may potentially affect the CYP activity. In this report, we therefore, intended to screen the novel PXR-dependent CYP3A4 activation potential of 58 medicinal plants of 27 families using cultured hepatocytes and reporter gene assay.

2. Experimental methods {#s0010}
=======================

2.1. Plant materials and extraction {#s0015}
-----------------------------------

The studied plant extracts included pre-identified, non-cytotoxic medicinal plants ([Table 1](#t0005){ref-type="table"}) with their traditionally known or published therapeutic values ([@b0010]). The dried plant parts were ground to a coarse powder using mortar-pestle and extracted with 80% ethanol (Merck, Germany) for three days with periodic shaking and filtered using Whatman No. 1 paper (Sigma, Germany). After removal of the solvent under reduced pressure using rotary evaporator (4 °C) and complete drying, their yield percentage were calculated. Stock of each extract (100 mg/ml) was prepared by dissolving in dimethyl sulfoxide (DMSO, Sigma, USA), and stored at -20 °C.Table 1List of medicinal plants (n = 58) screened for PXR-mediated CYP3A4 induction activity.No.Specimen no.Plants nameFamilyPlant part used116011*Achyranthe aspera*AmaranthaceaeShoots216391*Alternanthera pungens*Shoots316189*Amaranthus alba*Shoots416196*Avera Javanica*Shoots516198*Flaveria trineriva*AsteraceaeShoots616083*Pulicaria crispa*Shoots716075*Pergularia tomentosa*AsclepiadaceaeShoots816318*Eruca sativa*BrassicaceaeLeaves, Stems915841*Capparis decidua*CapparaceaeStems1016195*Atriplex suberecta*ChenopodiaceaeShoots1115496*Combretum molle*CombretaceaeBark12798*Guiera senegalensis*Leaves1316075*Ipomoea cairica*ConvolvulaceaeShoots1416179*Juniperus phonicea*CupressaceaeLeaves, Stems1516194*Juniperus procera*Leaves, Stems1615830*Cleome droserifolia*CrassulaceaeShoots1716275*Coccinia grandis*CucurbitaceaeLeaves, Stems1816393*Corallocarpus epigeus*Leave*s*1916395*Momordica balsamina*Leave*s*2016181*Chenopodium ambrosioides*Arial parts2116197*Chenopodium glaucum*Leaves, Stem2216172*Euphorbia tirucalli*EuphorbiaceaeStems2316084*Euphorbia hirta*Shoots2415189*Jatropha curcas*Seeds2514005*Ricinus communis*Leave*s*2616281*Acacia mellifera*FabaceaeLeave*s*2716221*Acacia hamulosa*Leaves, Stems2816387*Acacia asak*Leave*s*2916385*Acacia ehrenbergiana*Stems3016390*Acacia laeta*Stems3116389*Acacia oerfota*Stems3215007*Acacia salicina*Leave*s*3314977*Acacia tortilis*Stems3416182*Albizia procera*Leaves3516035*Delonix elata*Leave*s*3616183*Delonix regia*Leave*s*3716392*Indigofera coerulea*Shoots3816390*Indigofera tinctoria*Shoots39160322*Senna obtusifolia*Fruits40155009*Senna occidentalis*Fruits4116245*Senna alexandrina*Leave*s*4216301*Fumaria parviflora*FumariaceaeLeaves, Stems4316043*Marrubium vulgare*LabiataeShoots4415716*Cassytha filiformis*LauraceaeStems4516082*Abutilon figarianum*MalvaceaeLeave*s*4616080*Ficus benghalensis*MoraceaeLeaves, Stems4715448*Ficus palmata*Leave*s*4816085*Psidium guajava*MyrtaceaeLeave*s*4916184*Boerhavia diffusa*NyctaginaceaeLeaves5016177*Bougainvillea spectabilis*Leave*s*5116185*Argemone ochroleuca*PapaveraceaeShoots5216186*Rumex dentatus*PolygonaceaeShoots5316173*Citrus maxima*RutaceaeLeave*s*5415787*Dodonea angustifolia*SapindaceaeLeave*s*5515604*Daturai noxia*SolanaceaeLeave*s*5616386*Solanum surrattense*Leave*s*5712788*Clerodendrum inerme*VerbenaceaeLeaves, Stems58560*Balanites aegyptiaca*ZygophyllaceaeBark

2.2. Cell culture and reagents {#s0020}
------------------------------

Human hepatoblastoma cell line, HepG2 ([@b0090]) was maintained in T75 culture flask (Corning, USA) in RPMI-1640 medium (Gibco, Thermo Fisher Scientific, Inc., MA, USA), supplemented with 10% heat-inactivated bovine serum (Gibco, MA, USA), 1× penicillin-streptomycin (Gibco, MA, USA) and 1× sodium pyruvate (GE Healthcare Life Sci., UT, USA) in an incubator at 37 °C with 5% CO~2~ supply. Dimethyl sulphoxide (DMSO; Sigma, Germany) was used as carrier to prepare stocks of plants extracts or compounds as well as negative control. Rifampicin (Sigma, Germany) was used as standard PXR-mediated CYP3A4 inducer or positive control.

2.3. Plasmid DNA preparations {#s0025}
-----------------------------

The nuclear receptor expression vector *pCDG-hPXR* and CYP3A4 firefly-luciferase reporter construct *pGL3-CYP3A4-XREM* were kind gifts from Dr. Ron Evans (The Salk Institute for Biological Studies, La Jolla, USA) and Dr. Richard Kim (Department of Physiology and Pharmacology, University of Western Ontario, London, Canada), respectively. The renilla-luciferase expression plasmid (*pRL-TK*; Promega, USA) served as internal control. All plasmid DNA were transformed into DH5α XL competent cells (Invitrogen, USA) by the heat-shock method and plated on ampicillin (50 μg/ml) containing agar plates. Following an overnight incubation at 37 °C, bacterial colonies were picked and plasmids (Qiagen Plasmid Mini-prep Kit, Germany) were screened by restriction digestion. Further, DNA stocks were prepared (Qiagen Plasmid Maxi-prep Kit, Germany), quantified (Nanodrop 3300) and stored at −20 °C.

2.4. Transient transfection {#s0030}
---------------------------

HepG2 cells were seeded in 24-well culture plates (Corning, USA) and incubated overnight to reach up to 60--70% confluency. Next day, cells were co-transfected with *pGL3-CYP3A4-XREM* (CYP, 400 ng), *pCDG-hPXR* (PXR, 400 ng) and *pRL-TK* (200 ng), using transfection reagent FuGENE6 (Promega, USA) per well. A mock transfection control (negative, without plasmid) was also included. For a 24-well plate (200 μl media/well), the amount of FuGENE6 to DNA per well (3:1) was optimized as per the FuGENE6 manual. After 24 h, the medium was removed and 200 μl/well of fresh medium containing DMSO (0.1%) or rifampicin (10 μM) or plant extracts (50 μg/ml) was added. The treated cells were further incubated for 24 h at 37 °C. The cells were transfected in triplicate for all samples, including controls.

2.5. Luciferase reporter gene assay {#s0035}
-----------------------------------

After 24 h of treatment (48 h post-transfection), the reporter activities of firefly-luciferase and renilla-luciferase were measured with the Dual-Luciferase Reporter Assay System (Promega, USA) according to the manufacturer's manual. Briefly, reagents were brought to room temperature (RT), and reconstituted. Meanwhile, media were discarded and cells were carefully washed with 1× PBS (200 μl/well). The passive lysis buffer (1× PLB; 60 μl/well) was added and cells were allowed to lyse for 15 min at RT by gentle rocking (Heidolph DuoMax 1030, Heidolph instruments, GmBH, Germany). Total cell lysates were properly mixed and carefully harvested into pre-labeled 1.5 ml Eppendorf tubes. Lysates were quickly cleared at 10000 rpm for 30 sec (Eppendorf 5415D, USA) and placed in ice bath. The assay was instantly performed in round bottom high-clarity polypropylene tubes (5 ml; Falcon, USA) with 100 μl Luciferase Assay Reagent II or Stop & Glo Reagent and 10 μl lysate, using an illuminometer (Berthhold Lumat LB9507, Berthhold Technologies, USA). The assay was performed in triplicate for all samples and repeated. The firefly-luciferase signal was normalized to renilla-luciferase signal for each sample. To calculate fold-inductions, the ratios of all tested extracts were compared with normalized signals of the control. To determine the potency of the active extracts, concentrations \<50 μg/ml were also tested. All tests were performed in triplicate and repeated twice. Data was analyzed and represented as bar graph (Excel 2010; Microsoft, OK, USA).

2.6. Statistical analysis {#s0040}
-------------------------

All experiments were performed in triplicate and data were presented as the mean ± standard error, and were analyzed by One Way ANOVA using GraphPad Prism 7.04. The statistical differences between the control (CYP + PXR only) and treatment groups were carried out using Dunnett's Test (*P* value \<0.05).

3. Results {#s0045}
==========

3.1. PXR-dependent CYP3A4 induction by plant extracts {#s0050}
-----------------------------------------------------

For PXR-dependent CYP3A4 induction, a 50 μg/ml concentration was used for all non-cytotoxic plants ethanol extracts. Of the 58 plants extracts screened, four showed induction of PXR-mediated CYP3A4 expression. The comparative fold-induction of CYP34A by the plant extracts in relation to the untreated (DMSO) control was determined ([Fig. 1](#f0005){ref-type="fig"}). The induction activities of the tested plants were in the order, *Dodonaea angustifolia* (2.62 fold, *P* \< 0.0001), *Euphorbia tirucalli* (1.95 fold, *P* = 0.0004), *Alternanthera pungens* (1.74 fold, *P* = 0.0035), *Ficus palmata* (1.65 fold, *P* = 0.0097); and the rifampicin mediated fold of induction was 1.42 (*P* = 0.1209).Fig. 1Reporter gene assay, showing fold-activation of PXR-mediated CYP3A4 expression in HepG2 cells upon treatment with rifampicin (10 μM) and different plant extracts (50 μg/ml). Data are presented as the mean ± standard error (n = 3). ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 vs. CYP + PXR only (DMSO control) group. PXR: pCDG-hPXR; CYP: pGL3-CYP3A4-XREM; F. palmate: *Ficus palmate*; A. pungens: *Alternanthera pungens*; E. tirucalli: *Euphorbia tirucalli*; D. angustifolia: *Dodonaea angustifolia*.

4. Discussion {#s0055}
=============

The PXR-mediated CYP3A4 expression is markedly induced in cultured human hepatocytes in response to a variety of xenobiotics and drugs, including some bioactive plant products. In this study, we have therefore, screened ethanol extracts of 58 medicinal plants using HepG2 cell culture and dual-luciferase assay for their PXR-mediated CYP3A4 activation potential. All the non-toxic extracts were tested at the safe concentration 50 μg/ml as compared to a similar study where extracts at 100 μg/ml doses were used ([@b0085]).

*Dodonaea angustifolia* (sand olive) occurs naturally in Arabia and southern Africa, including Australia and New Zealand. An important traditional medicine of Africa, its leaves decoction is used for fever, colds, flu, stomachache, measles, tuberculosis and skin rashes ([@b0120]). However, very limited studies have been published on *Dodonaea angustifolia* and none on its chemical constituents compared to its other species. A single study has reported presence of flavonoids, reducing sugars, alkaloids, saponins and tannin in its leaves ([@b0005]). Here, we have for the first time, demonstrated its very promising activation potential of PXR-mediated CYP3A4 expression in HepG2 cells.

*Euphorbia tirucalli* (firestick or milk bush) has a wide distribution in Arabia and Africa, including many other tropical regions. It is a hydrocarbon plant that produces a poisonous latex, possibly convertible to biofuel ([@b0030]). It is used in traditional medicine for cancer, excrescence, tumors, warts, asthma, cough, earache, neuralgia and rheumatism ([@b0025]). In this study, we report a novel PXR-mediated CYP3A4 activation property of *Euphorbia tirucalli* in HepG2 cells.

*Alternanthera pungens* (Kunth) is a ruderal plant of roadsides, path verges and waste places. Though a native of South America, it is also reported from other tropical countries including India ([@b0055]). Compared to its other species, *Alternanthera pungens* is poorly studied. In a very recent study, its crude extract is shown to have a wide spectrum antibacterial activity as well as good antioxidant potential ([@b0055]). Here, we have demonstrated the novel PXR-mediated CYP3A4 activation potential *Alternanthera pungens* in HepG2 cells.

*Ficus palmata* (Fegra or Wild Himalayan Fig) occurs in North West India, Afghanistan, Iran, Arabia and Africa ([@b0060]). It is used as hypoglycemic, anti-tumour, anti-ulcer, anti-diabetic, lipid lowering and antifungal remedy, including nephro-hepatoprotective effect ([@b0060]). In this report, we have shown a novel PXR-mediated CYP3A4 inducing activity of *Ficus palmata* in HepG2 cells.

5. Conclusion {#s0060}
=============

Our screening of ethanol extracts of 58 medicinal plants using HepG2 cells and reporter gene assay, has demonstrated the novel PXR-mediated CYP3A4 gene induction potential of four plants. Of these, *Dodonaea angustifolia* was found to be the most promising CYP3A4 activator, followed by *Euphorbia tirucalli*, *Alternanthera pungens*, and *Ficus palmata*. Further phytochemical characterizations, including isolation of active principles are therefore, warranted.
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